CA2599531A1 - Metformin methods and formulations for treating chronic constipation - Google Patents

Metformin methods and formulations for treating chronic constipation Download PDF

Info

Publication number
CA2599531A1
CA2599531A1 CA002599531A CA2599531A CA2599531A1 CA 2599531 A1 CA2599531 A1 CA 2599531A1 CA 002599531 A CA002599531 A CA 002599531A CA 2599531 A CA2599531 A CA 2599531A CA 2599531 A1 CA2599531 A1 CA 2599531A1
Authority
CA
Canada
Prior art keywords
metformin
formulation
release
pharmaceutically acceptable
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002599531A
Other languages
English (en)
French (fr)
Inventor
John Devane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGI Therapeutics Research Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2599531A1 publication Critical patent/CA2599531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002599531A 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation Abandoned CA2599531A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66292005P 2005-03-18 2005-03-18
US60/662,920 2005-03-18
PCT/IB2006/002233 WO2007007189A2 (en) 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation

Publications (1)

Publication Number Publication Date
CA2599531A1 true CA2599531A1 (en) 2007-01-18

Family

ID=37637555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002599531A Abandoned CA2599531A1 (en) 2005-03-18 2006-03-16 Metformin methods and formulations for treating chronic constipation

Country Status (10)

Country Link
US (1) US20060222709A1 (https=)
EP (1) EP1865939A2 (https=)
JP (1) JP2008533127A (https=)
AU (1) AU2006268003A1 (https=)
CA (1) CA2599531A1 (https=)
IL (1) IL185652A0 (https=)
MX (1) MX2007011174A (https=)
NO (1) NO20075344L (https=)
WO (1) WO2007007189A2 (https=)
ZA (1) ZA200707325B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744817C (en) * 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) * 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) * 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
HUE051738T2 (hu) 2011-01-07 2021-03-29 Anji Pharma Us Llc Kemoszenzoros receptorligandum-alapú terápiák
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
EP2599789A1 (en) * 2011-12-01 2013-06-05 Bergen Teknologioverføring AS Marker and method for diagnosing diarrhea syndrome
EA033067B1 (ru) * 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
CA2878625A1 (en) * 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN104936581A (zh) * 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法
CN105101956B (zh) * 2013-01-05 2018-12-07 埃尔舍利克斯治疗公司 包含双胍的延迟释放组合物
CN104434846A (zh) * 2014-11-17 2015-03-25 中国药科大学 盐酸二甲双胍肠溶缓释微丸及其制备方法
TW201938147A (zh) * 2017-12-18 2019-10-01 德商拜耳廠股份有限公司 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法
CN114555811B (zh) 2019-10-16 2025-03-25 拜耳公司 用于改善阿卡波糖形成的方法
EP4615423A1 (en) 2022-11-07 2025-09-17 Rejuvenate Biomed NV Metformin minitablets
CN121846068A (zh) * 2023-08-22 2026-04-14 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
HK1040910B (en) * 1998-11-12 2009-06-26 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and metformin
US6676966B1 (en) * 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
IL185652A0 (en) 2008-01-06
WO2007007189A3 (en) 2007-04-26
NO20075344L (no) 2007-10-18
JP2008533127A (ja) 2008-08-21
ZA200707325B (en) 2009-03-25
US20060222709A1 (en) 2006-10-05
MX2007011174A (es) 2008-02-11
WO2007007189A2 (en) 2007-01-18
AU2006268003A1 (en) 2007-01-18
EP1865939A2 (en) 2007-12-19

Similar Documents

Publication Publication Date Title
US20060222709A1 (en) Metformin methods and formulations for treating chronic constipation
RU2207856C2 (ru) Способ лечения сердечно-сосудистых заболеваний
JP5783489B2 (ja) トロスピウムの１日１回剤形
US6156343A (en) Controlled release preparation
JP4072597B2 (ja) 持続性製剤
US20040202718A1 (en) Dosage form for treatment of diabetes mellitus
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20030133982A1 (en) Zero-order sustained release dosage forms and method of making same
JPH061716A (ja) 活性成分の長期放出性を有する投薬形
US20070160671A1 (en) Biguanide formulations
CZ20001200A3 (cs) Prostředek pro řízené podávání účinných látek
CN107530337A (zh) 治疗方法
US20060229261A1 (en) Acarbose methods and formulations for treating chronic constipation
EP1891947A2 (en) Use of (r)-verapamil for the treatment of abnormal increases in gastrointestinal motility
EP1216032B1 (en) Oral controlled release formulations
KR100591142B1 (ko) 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
CN101516353B (zh) 包含核心和一个或多个阻挡层的控释口服制剂
EP3796908B1 (en) Controlled release propiverine formulations
WO2006080630A1 (en) Pharmaceutical combination preparation for oral delivery for the treatment of diabetes mellitus
WO2025242589A1 (en) Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy
TW201609196A (zh) 控制釋放製劑及其製備方法
AU2002348712A1 (en) Dosage form for treatment of diabetes mellitus
MXPA06004017A (es) Formas de dosis una vez al dia de trospio

Legal Events

Date Code Title Description
FZDE Discontinued